Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkac425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Tomefa E Asempa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Ceftazidime, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Food and Drug Administration.
Abstract (Originalsprache)
Background
Two of the three recently approved β-lactam agent (BL)/β-lactamase inhibitor (BLI) combinations have higher CLSI susceptibility breakpoints (ceftazidime/avibactam 8 mg/L; meropenem/vaborbactam 4 mg/L) compared with the BL alone (ceftazidime 4 mg/L; meropenem 1 mg/L). This can lead to a therapeutic grey area on susceptibility reports depending on resistance mechanism. For instance, a meropenem-resistant OXA-48 isolate (MIC 4 mg/L) may appear as meropenem/vaborbactam-susceptible (MIC 4 mg/L) despite vaborbactam’s lack of OXA-48 inhibitory activity.
Methods
OXA-48-positive (n = 51) and OXA-48-negative (KPC, n = 5; Klebsiella pneumoniae wild-type, n = 1) Enterobacterales were utilized. Susceptibility tests (broth microdilution) were conducted with ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam, as well as their respective BL partner. Antimicrobial activity of all six agents was evaluated in the murine neutropenic thigh model using clinically relevant exposures. Efficacy was assessed as the change in bacterial growth at 24 h, compared with 0 h controls.
Results
On average, the three BL/BLI agents resulted in robust bacteria killing among OXA-48-negative isolates. Among OXA-48-positive isolates, poor in vivo activity with imipenem/relebactam was concordant with its resistant phenotypic profile. Variable meropenem/vaborbactam activity was observed among isolates with a ‘susceptible’ MIC of 4 mg/L. Only 30% (7/23) of isolates at meropenem/vaborbactam MICs of 2 and 4 mg/L met the ≥1-log bacterial reduction threshold predictive of clinical efficacy in serious infections. In contrast, ceftazidime/avibactam resulted in marked bacterial density reduction across the range of MICs, and 96% (49/51) of isolates exceeded the ≥1-log bacterial reduction threshold.
Conclusions
Data demonstrate that current imipenem/relebactam and ceftazidime/avibactam CLSI breakpoints are appropriate. Data also suggest that higher meropenem/vaborbactam breakpoints relative to meropenem can translate to potentially poor clinical outcomes in patients infected with OXA-48-harbouring isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
ORCID-Profile: Tomefa E Asempa, David P Nicolau
Förderung
- Food and Drug Administration
Zitieren
APA
Asempa, T. E., Kois, A. K., Gill, C. M., & Nicolau, D. P. (2023). Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac425
Vancouver
Asempa TE, Kois AK, Gill CM, Nicolau DP. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac425
BibTeX
@article{Asempa2023,
author = {Asempa, Tomefa E and Kois, Abigail K and Gill, Christian M and Nicolau, David P},
title = {Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkac425}
}
EUVIMED